For 2013-2014, UTRF has acquired funds to pay for some early stage drugability assays.
To add commercial value to UTHSC technologies by acquiring early stage drugability data (ADME-tox, PK/PD) on small molecules and early development assays for biologics.
- Compound structure or type of biologic
- Brief overview of biological data: in vitro data and in vivo proof of concept data.
- Any ADME-tox studies to date and summary of results.
Compounds submitted for the tests must be >95% pure, as determined by 1H NMR and HPLC-MS. Funds will not be available to pay for the re-synthesis of compounds. The program will be open to requests anytime throughout the year. The exact drugability tests for each request will be chosen based on type/stage of project, input from PI and assays that are determined to increase chances for commercialization. No funds will be distributed. All scheduling and billing with contract research organizations will be through UTRF. All data from the contract research organizations will be obtained by UTRF and distributed to inventors. Inventors may use the data for publications, presentations and grant proposals. Examples of small molecule assays that may be requested and/or proposed: aqueous solubility, CYP inhibition, metabolic stability, CACO-2, hERG patchclamp, iv/oral rat PK, off-target screening.